Upscheduling codeine-containing OTCs could cost upwards of $1.27 billion in MBS outlay alone over the next four years, a new report has found. The Pharmacy Guild engaged Cadence Economics to undertake an analysis of the fiscal impacts of upscheduling all medicines containing codeine to prescription only. Currently there are 16.4 million units sold each year
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.